Merck & Co., Inc. (NYSE: MRK)
Health Care · Pharmaceuticals · US
$152.27
-0.18% today · +77.2% 1Y
Merck & Co., Inc. (NYSE: MRK) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $376.37B and employs 74,000 people.
Over the last twelve months the share price has gained 77.2%, trading between 77.58 and 153.50.
Tweenvest scores Merck & Co., Inc. across four factors: quality 81/100, value 19/100, growth 40/100, dividend 75/100. Its strongest factor is quality.
MRK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $376.37B
- Revenue (TTM)
- $66.57B
- P/E
- 119.85
- EPS
- 1.27
- Dividend yield
- 2.28%
- Beta (5Y)
- 0.21
- 52-week high
- $153.50
- 52-week low
- $77.58
- Avg volume (3M)
- —
- Shares outstanding
- 2.47B
- Employees
- 74,000
- Next earnings
- —
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- ISIN
- US58933Y1055
- Founded
- 1891
- Listed since
- Jan 13, 1978
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,256.59 | +0.09% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.08 | +0.31% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.30 | -1.41% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.00 | -1.14% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.12 | +0.18% |
| Bristol-Myers Squibb CompanyNYSE: BMY | $136.88B | $67.38 | +0.55% |
Figures last refreshed Aug 18, 2026.